Search

Author/Creator Albert, Gary

1. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Issue 5 (May 2022)

Authors:
Madhi, Shabir A; Moodley, Dhayendre; Hanley, Sherika; Archary, Moherndran; Hoosain, Zaheer; Lalloo, Umesh; Louw, Cheryl; Fairlie, Lee; Fouche, Leon Frederik; Masilela, Mduduzi S L; Singh, Nishanta; Grobbelaar, Coert; Ahmed, Khatija; Benadé, Gabriella; Bhikha, Sutika; Bhorat, As'ad Ebrahim; Bhorat...
Journal:
Lancet
Issue:
Volume 9:Issue 5(2022)
Page Start:
e309
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Issue 11 (November 2022)

Authors:
Mallory, Raburn M; Formica, Neil; Pfeiffer, Susan; Wilkinson, Bethanie; Marcheschi, Alex; Albert, Gary; McFall, Heather; Robinson, Michelle; Plested, Joyce S; Zhu, Mingzhu; Cloney-Clark, Shane; Zhou, Bin; Chau, Gordon; Robertson, Andreana; Maciejewski, Sonia; Hammond, Holly L; Baracco, Lauren; Lo...
Journal:
Lancet infectious diseases
Issue:
Volume 22:Issue 11(2022)
Page Start:
1565
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search